Pegaptanib octasodium for the treatment of diabetic macular edema

Author： Schartman Jerome P   Coney Joseph M   Hornik Joan H   Miller David G  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.12, Iss.8, 2011-06, pp. : 1317-1323

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Emerging pharmacotherapies for diabetic macular edema

By Furlani Bruno A   Meyer Carsten H   Rodrigues Eduardo B   Maia Mauricio   Farah Michel E   Penha Fernando M   Holz Frank G  

Expert Opinion on Emerging Drugs, Vol. 12, Iss. 4, 2007-11 ,pp. : 591-603

Informa Healthcare

Access to resources Recommend Favorite

Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implant

By Ciulla Thomas A   Harris Alon   McIntyre Nathaniel   Jonescu-Cuypers Christian  

Expert Opinion on Pharmacotherapy, Vol. 15, Iss. 7, 2014-05 ,pp. : 953-959

Informa Healthcare

Access to resources Recommend Favorite

Anti-VEGF Molecules for the Management of Diabetic Macular Edema

By  

Current Pharmaceutical Design, Vol. 21, Iss. 32, 2015-10 ,pp. : 4731-4737

Bentham Science Publishers

Access to resources Recommend Favorite

Cost Effectiveness of Pegaptanib for the Treatment of Age-Related Macular Degeneration in the UK

By Wolowacz Sorrel E.  

PharmacoEconomics, Vol. 25, Iss. 10, 2007-01 ,pp. : 863-879

Adis International

Access to resources Recommend Favorite

Pegaptanib sodium for the treatment of neovascular age-related macular degeneration

By Moshfeghi Andrew A   Puliafito Carmen A  

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 5, 2005-05 ,pp. : 671-682

Informa Healthcare

Access to resources Recommend Favorite